Über ein Jahr B-Zell-gerichtete Therapie mit Ofatumumab s.c.: erste Ergebnisse einer prospektiven, patientenzentrierten Real-world-Beobachtungsstudie

INTRODUCTION: Ofatumumab (Kesimpta™) is a s.c. applicable anti-CD20 antibody, which has been used in Germany since 2021 for the treatment of relapsing multiple sclerosis (RMS). The self-application offers a high degree of independence from intravenous forms of application with highly effective immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Klimas, Rafael, Karl, Anna-Sophia, Poser, Philip Lennart, Sgodzai, Melissa, Theile-Ochel, Simon, Gisevius, Barbara, Faissner, Simon, Nastos, Ilias, Gold, Ralf, Motte, Jeremias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2023
Materias:
Originalien
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576000/
https://www.ncbi.nlm.nih.gov/pubmed/37042954
http://dx.doi.org/10.1007/s00115-023-01470-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576000/
https://www.ncbi.nlm.nih.gov/pubmed/37042954
http://dx.doi.org/10.1007/s00115-023-01470-y

Ejemplares similares